Analyst Research Report Snapshot

Title:

ABLYNX - FOCUS MOVES TO PARTNERING

Price:

$10.00

Provider:

Edison Investment Research

Date:

12 Mar 2013

Pages:

9

Type:

AcrobatPDF

Companies referenced:

ABLX.BR

Available for Immediate Download
Summary:

Ablynx’s investment case in the near term hinges on its ability to partner its IL-6R Nanobody, ALX-0061, using the final results from the Phase I/II study in rheumatoid arthritis (RA). The 24-week data suggests that ALX-0061 might have a superior efficacy and safety profile to Roche’s tocilizumab (Actemra, an IL-6R monoclonal antibody) and other IL-6 inhibitors in development. The partnering of ALX-0061 could still be challenging because of the competitive nature of RA, but Ablynx has raised €31.5m to maintain momentum in the programme. We value the company at €431m, which rises to €497m if ALX-0061 is out-licensed.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.